CSF2 and COVID-19: One China-based CAR trial initiated in March 2020 employs dual-targeting anti-NKG2D-ACE2 CAR-NK cells, which secretes IL-15 superagonist for NK cell longevity and has a GM-CSF neutralizing receptor to prevent cytokine release syndrome, in COVID-19 patients (NCT04324996).